

# VACCINE POINTS

“Vaccine Points” is a bi-monthly communication distributed by the Hawaii Department of Health to all participating Vaccines for Children (VFC) providers.

Test your vaccine knowledge.

Question:

Which of the following persons, if any, is/are recommended by the ACIP to receive serogroup B meningococcal (MenB) vaccine?

Select all that apply.

- a) All incoming first-year college students living in residence halls
- b) Persons with persistent complement component deficiencies
- c) Microbiologists routinely exposed to isolates of *Neisseria meningitidis*
- d) Persons who travel to areas where meningococcal disease is hyperendemic or endemic
- e) 2 year old with functional asplenia

Answer:

b, c



Unlike quadrivalent meningococcal conjugate vaccine (MenACWY) which is routinely recommended for all children at age 11 through 12 years, with a booster dose at age 16 years, MenB vaccine is recommended for those at increased risk for meningococcal disease, and based on clinical decision-making, may be administered to adolescents and young adults.

Certain persons aged  $\geq 10$  years who are at increased risk for meningococcal disease should receive MenB vaccine, including:

- Persons with persistent complement component deficiencies
- Microbiologists routinely exposed to isolates of *Neisseria meningitidis*

The vaccine is *not* currently recommended for routine use in first-year college students living in residence halls, but MAY be administered to adolescents and young adults (16 through 23 years of age, preferably at 16 through 18 years of age) to provide short-term protection against most strains of serogroup B meningococcal disease. MenB is not recommended for persons who travel to or reside in countries where meningococcal disease is hyperendemic or endemic because the risk for meningococcal disease in these countries generally is not caused by serogroup B.

MenB vaccines are not licensed for children aged  $< 10$  years and are not currently recommended for children aged 2 months – 9 years who are at increased risk for serogroup B meningococcal disease.

Source:

MIMWR, Use of Serogroup B Meningococcal Vaccines in Persons Aged  $\geq 10$  Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015 <https://www.cdc.gov/mimwr/preview/mimwrhtml/m6422a3.htm>

MIMWR, Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015 <https://www.cdc.gov/mimwr/preview/mimwrhtml/m6441a3.htm>